证券之星消息，1月15日化学制药板块较上一交易日下跌1.4%，向日葵领跌。当日上证指数报收于 4112.6，下跌0.33%。深证成指报收于14306.73，上涨0.41%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300452 | 山河药辅 | 16.85 | 20.01% | 41.42万 | | 6.70亿 | | 301075 | 多瑞医药 | 62.71 | 11.48% | 2.65万 | | 1.65 Z | | 688176 | 亚虹医药 | 13.16 | 7.69% | 26.47万 | | 3.45亿 | | 300401 | 化园生物 | 16.52 | 3.57% | 1 50.30万 | | 8.28亿 | | 000739 | 普洛药业 | 18.13 | 3.30% | 27.08万 | | 4.87亿 | | 002923 | 润都股份 | 13.04 | 3.16% | 9.42万 | | 1.23亿 | | ...

中国经济网北京1月15日讯 向日葵(300111.SZ)今日一字跌停，截至收盘报4.96元，跌幅20.00%。 昨日晚间，向日葵发布关于收到中国证券监督管理委员会《立案告知书》的公告。公司于2026年1 月14日收到中国证监会下发的《立案告知书》（编号：证监立案字01120260003号），因公司涉嫌信息 披露违法违规，根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监 会决定对公司进行立案。 (责任编辑：田云绯) 因公司收到中国证券监督管理委员会出具的《立案告知书》，根据《上市公司重大资产重组管理办 法》的规定，公司不符合发行股份购买资产的条件，因此决定终止本次重组事项。 向日葵表示，公司与交易相关方签署的与本次交易相关的发行股份及支付现金购买资产协议尚未生 效。因公司收到中国证券监督管理委员会出具的《立案告知书》，根据《上市公司重大资产重组管理办 法》的规定，公司不符合发行股份购买资产的条件，因此决定终止本次重组事项。本次重组事项的终止 不会对公司生产经营产生重大不利影响。 向日葵表示，公司将积极配合中国证监会的立案调查工作，严格按照相关法律法规的规定和监管要 求，及时履行信息披 ...

Core Viewpoint - The company Sunflower is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure, leading to the termination of its semiconductor cross-border restructuring plan [1][5][21]. Group 1: Investigation and Impact - Sunflower's stock opened with a 20% limit down, currently priced at 4.96 yuan, with a total market value of 6.385 billion yuan [2]. - The company's stock has retraced over 40% from its peak last year [3]. - The CSRC issued a notice of investigation on January 14, 2026, due to misleading statements regarding the actual production capacity and business model of the restructuring targets [5][9]. Group 2: Restructuring Attempts - The planned restructuring involved acquiring 100% of Xipu Materials and 40% of Beid Pharmaceutical, with the intention to raise funds through a share issuance to specific investors [8]. - The restructuring plan was terminated following the CSRC's investigation, which deemed the proposal as containing misleading statements [8][21]. - This marks the end of Sunflower's attempt to transition into the semiconductor industry, which was seen as a significant shift from its previous focus on pharmaceuticals [10][21]. Group 3: Historical Context - Sunflower has attempted four cross-border transitions since its establishment, with only the first being successful [22]. - The company originally focused on crystalline silicon solar cells but shifted to pharmaceuticals in 2019 due to market pressures [23]. - Recent attempts to return to the solar industry and enter the metal-based ceramic materials sector were unsuccessful due to funding issues and unmet technical standards [24]. Group 4: Financial Performance - Sunflower has struggled near the breakeven point in recent years, with revenues of 297 million yuan, 336 million yuan, 338 million yuan, and 330 million yuan from 2021 to 2024, and fluctuating net profits [25]. - In the first half of 2025, the company reported a revenue of 144 million yuan, a year-on-year decline of 8.33%, and a net profit of 1.1607 million yuan, down 35.68% [25]. - For the first three quarters of 2025, revenue was 200 million yuan, a 12.09% decrease year-on-year, with a net profit of 1.3062 million yuan, down 53.10% [25].

Core Viewpoint - Zhejiang Sunflower (stock code: 300111) has received a notice from the China Securities Regulatory Commission (CSRC) regarding potential administrative penalties for suspected violations of information disclosure laws [1] Group 1: Company Announcement - The company has stated that it has not yet received the final penalty decision from the CSRC, and the outcome will depend on the formal decision issued by the CSRC [1] - According to the Securities Law and relevant judicial interpretations, if a listed company causes investor losses due to false statements, it must bear civil compensation responsibilities [1] Group 2: Investor Compensation - Preliminary compensation scope includes investors who purchased Sunflower stock between its listing and before the market close on January 15, 2026, and still hold the stock at that time [2] - Investors are required to prepare specific materials, including original transaction statements stamped by the brokerage, copies of their ID cards, and a securities account information query issued by the brokerage [3][4] Group 3: Legal Perspective - The preliminary registration conditions for compensation are based on publicly available information and relevant laws, and may be adjusted as regulatory investigations and judicial processes progress [5]

登录新浪财经APP 搜索【信披】查看更多考评等级 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我 上海久诚律师事务所股票索赔律师许峰提示，向日葵（维权）（300111）虚假陈述引发的投资者索赔案 已经启动。（许峰律师专栏） 2026年1月14日晚，向日葵（300111）公告于2026年1月14日收到证监会下发的《立案告知书》（编号： 证监立案字01120260003号），因公司涉嫌信息披露违法违规，根据《证券法》《行政处罚法》等法律 法规，证监会决定对公司进行立案。 1月14日晚，证监会官微发布信息称，2025年9月22日，浙江向日葵大健康科技股份有限公司披露重组预 案。近期，重组标的的实际产能和业务模式引发市场质疑，浙江证监局依法开展核查工作，发现重组预 案涉嫌误导性陈述，已于近日对向日葵立案调查。下一步，将在全面调查的基础上依法处理，切实维护 并购重组市场秩序。 2026年1月14日晚，向日葵（300111）公告于2026年1月14日收到证监会 ...

Core Viewpoint - Zhejiang Sunflower's major asset restructuring plan to acquire 100% equity of Zhangzhou Xipu Materials Technology Co., Ltd. and 40% equity of Zhejiang Beid Pharmaceutical Co., Ltd. has been terminated due to the issuance of a notice of investigation by the China Securities Regulatory Commission (CSRC) for misleading statements in the restructuring proposal [1][4][8]. Group 1: Restructuring Announcement and Investigation - On January 14, Zhejiang Sunflower announced the termination of its asset restructuring plan after receiving a notice from the CSRC [1]. - The CSRC has initiated an investigation into the company for allegedly misleading statements in the restructuring proposal, with the Zhejiang Securities Regulatory Bureau taking action to maintain market order [4][8]. Group 2: Market Reaction - Following the announcement, Zhejiang Sunflower's stock hit the daily limit down, falling by 20% to a price of 4.96 yuan per share, resulting in a total market capitalization of approximately 6.385 billion yuan [4][5]. Group 3: Historical Context and Financial Performance - The company has a history of attempting cross-industry transformations, including a shift from photovoltaic to pharmaceutical sectors, and more recently to semiconductor materials, all of which have faced challenges and terminations [9][10]. - Financially, the company has experienced unstable performance, with revenues from 2021 to 2024 showing fluctuations, and a significant decline in net profit in the first three quarters of 2025 compared to the previous year [11].

Core Viewpoint - The company Xiangrikui (300111.SZ) faced a significant drop in stock price due to a regulatory investigation by the China Securities Regulatory Commission (CSRC) regarding alleged misleading statements in its restructuring proposal [1][2]. Group 1: Regulatory Investigation - On January 14, the CSRC issued a notice to Xiangrikui, indicating that the company is under investigation for suspected violations of information disclosure laws [1]. - The Zhejiang Securities Regulatory Bureau is investigating the restructuring proposal for misleading statements, particularly concerning the actual production capacity and business model of the acquisition targets [1][3]. - As a result of the investigation, Xiangrikui announced the termination of its restructuring plans, as it no longer meets the conditions for issuing shares to purchase assets [1][2]. Group 2: Financial Performance - In the first three quarters of 2025, Xiangrikui reported revenue of 200 million yuan, a year-on-year decrease of 12.09%, and a net profit attributable to shareholders of 1.31 million yuan, down 53.10% year-on-year [3]. - The company's stock price fell to 4.96 yuan per share, representing a 20% decline, with a total market capitalization of 6.385 billion yuan [1][4]. Group 3: Acquisition Targets - Xiangrikui planned to acquire 100% of Zhangzhou Xipu Material Technology Co., Ltd. and 40% of Zhejiang Beide Pharmaceutical Co., Ltd. through a combination of share issuance and cash payment [2]. - The acquisition target, Xipu Material, is positioned in the semiconductor materials sector, which has garnered significant market attention [2]. - However, investigations revealed that the claimed production facilities of Xipu Material had not commenced operations, raising concerns about the accuracy of the company's statements [2].

21财经1月15日电，向日葵（300111.SZ）20cm一字跌停，报4.96元/股，总市值为63.85亿元。截至 10:28，"卖一"位置压单高达105万手。消息面上，向日葵发布公告称，公司于1月14日收到中国证监会 下发的《立案告知书》，因公司涉嫌信息披露违法违规，根据相关法律法规，中国证监会决定对公司进 行立案。因遭证监会立案，根据相关规定，公司已不符合发行股份购买资产的条件，重组事项宣告终 止。对于此次立案影响，21快讯记者以投资者身份致电向日葵，公司接线人员表示，尽管收购标的受到 质疑，但由于购买协议尚未正式生效，不会对公司生产经营产生重大不利影响。此外，该工作人员称尚 不清楚公司是否会被ST，"我们现在目前是在配合调查，所有东西都要等到有决定之后最终决定。"查 看原文：遭立案重组终止，股价一字跌停，向日葵回应10分钟前 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我 公司致力于医药、大健康和高科技产业投资，未来将打造医药创新、医疗器械和医药服务的大健康产业 集群和TMT方向的高科技产业集群，把握中国经济转型的机遇。公司愿景是"健康承载梦想，行动成就 未来"。 根据申万行业分类（2021），向日葵（维权）属于医药生物-化学制药-化学制剂。 2026年1月14日，公司收到中国证监会下发的《立案告知书》（编号：证监立案字01120260003号），因 公司涉嫌信息披露违法违规被立案调查。 立案后，公司股票的表现如下： 而在中国证券监督管理委员会的官网：发布了标题为《浙江证监局对向日葵重组预案涉嫌误导性陈述立 案调查》：2025年9月22日，浙江向日葵大健康科技股份有限公司（简称向日葵）披露重组预案。近 期，重组标的的实际产能和业务模式引发市场质疑，浙江证监局依法开展核查工作，发现重组预案涉嫌 误导性陈述。 初步判断：20 ...

中国基金报记者 晨曦 大家好！来一起关注最新的市场行情和资讯～ 1月15日，A股主要指数开盘集体飘绿，盘中短暂翻红后再度回调。截至发稿，上证指数跌0.27%，深证成指跌0.02%，创业板指跌0.59%。 盘面上，有色金属、基础化工、电力设备、建筑材料等板块走强，卫星导航、商业航天、军工信息化、6G等前期热门方向集体回调，多只前期高位股跳 水跌停。 来看详情—— 有色金属板块走强 基础化工盘中拉升 1月15日上午，有色金属板块高开高走，小金属赛道火热。四川黄金涨停，湖南白银涨超8%，华锡有色、华友钴业等跟涨。 | 序号 代码 | 名称 | 现价 | | 涨跌幅・ | | --- | --- | --- | --- | --- | | 1 - | 001337 四川黄金 | 34.64 | 3.15 | 10.00% | | N | 002716 湖南白银 | 10.73 | 0.81 | 8.17% | | ന | 600301 华锡有色 | 53.20 | 3.69 | 7.45% | | 4 | 601958 金铝股份 | 19.48 | 1.34 | 7.39% | | ഗ | 600497 驰宏锌铭 | ...